In August 2020, the Food and Drug Administration granted accelerated approval to belantamab mafodotin (BLENREP; GlaxoSmithKline), a BCMA-targeted antibody–drug conjugate for the treatment of patients with relapsed or refractory multiple myeloma [9]. Here, TNFRSF17 is linked to plasma cell myeloma.